While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ:GTHX) appears quite enticing. First and foremost, it levers acumen in the burgeoning small-molecule therapeutics space. Second, G1 Therapeutics stock seems undervalued for what speculators may be getting.Of course, to make the case that GTHX is a bullish idea, an investor must make two critical assumptio ...